The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value-Reference-Cited by-同舟云学术

The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value

Published:2022-02-16 Issue:1 Volume:78 Page:78-86
ISSN:1784-3286
Container-title:Acta Clinica Belgica
language:en
Short-container-title:Acta Clinica Belgica

Author:

Janssens Esther¹^ORCID,Flamaing Johan²³^ORCID,Vandermeulen Corinne³⁴^ORCID,Peetermans Willy E.¹⁵,Desmet Stefanie¹⁶,De Munter Paul¹⁵^ORCID

Affiliation:

1. Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

2. Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium

3. Department of Public Health & Primary Care, KU Leuven, Leuven, Belgium

4. Leuven University Vaccinology Centre, Leuven, Belgium

5. Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium

6. National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, Leuven, Belgium

Funder

public, commercial, or not-for-profit sectors

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17843286.2022.2039865

Reference45 articles.

1. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

2. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium

3. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15

4. Belgian superior health council: vaccination against pneumococci - guidelines in children (HGR 9519). 2018 Accessed 10 December 2020. Available from: https://www.health.belgium.be/nl/advies-9519-vaccinatie-tegen-pneumokokken-kinderen#anchor-34691.

5. Berete F, Tafforeau J, and Demarest S, et al. Gezondheidsenquête 2018: vaccinatie. Brussel, België: Sciensano Accessed 10 December 2020; Rapportnummer: D/2019/14.440/82. Rapportnummer: D/2019/14.440/82: www.gezondheidsenquete.be.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective Effects from Prior Pneumococcal Vaccination in Patients with Chronic Airway Diseases during Hospitalization for Influenza—A Territory-Wide Study;Vaccines;2024-06-23

2. Dynamics of <i>Streptococcus pneumoniae</i> serotype structure in children for the period 2016–2022;Epidemiology and Infectious Diseases;2024-06-10

3. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers;Pediatric Infectious Disease Journal;2024-03-08

4. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature;Human Vaccines & Immunotherapeutics;2023-11-28

5. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants;Vaccines;2023-08-15